These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12937850)

  • 1. Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities.
    Fedorocko P; Hoferová Z; Hofer M; Brezáni P
    Neoplasma; 2003; 50(3):176-84. PubMed ID: 12937850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.
    Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ
    J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse.
    Fedorocko P
    Int J Radiat Biol; 1994 Apr; 65(4):465-75. PubMed ID: 7908934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide.
    Saiki I; Milas L; Hunter N; Fidler IJ
    Cancer Res; 1986 Oct; 46(10):4966-70. PubMed ID: 3756858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance.
    Karpoff HM; Jarnagin W; Delman K; Fong Y
    Surgery; 2000 Aug; 128(2):213-8. PubMed ID: 10922994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin.
    Asao T; Shibata HR; Batist G; Brodt P
    Cancer Res; 1992 Nov; 52(22):6254-7. PubMed ID: 1423270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.
    Macková NO; Fedorocko P
    Neoplasma; 1993; 40(6):379-85. PubMed ID: 8289971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
    Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
    J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
    Shi F; MacEwen EG; Kurzman ID
    Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
    Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
    Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
    Kleinerman ES; Snyder JS; Jaffe N
    J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
    Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
    Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
    Fogler WE; Wade R; Brundish DE; Fidler IJ
    J Immunol; 1985 Aug; 135(2):1372-7. PubMed ID: 4008926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
    Maeda M; Asano T; Kleinerman ES
    Cancer Immunol Immunother; 1993 Aug; 37(3):203-8. PubMed ID: 8334682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal MTP-PE: a promising new biologic response modifier.
    Gano JB; Kleinerman ES
    Oncol Nurs Forum; 1995 Jun; 22(5):809-16. PubMed ID: 7675688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
    Maeda M; Knowles RD; Kleinerman ES
    Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined modality radioprotection: enhancement of survival and hematopoietic recovery in gamma-irradiated mice by the joint use of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin.
    Fedorocko P; Macková NO
    Int J Immunopharmacol; 1996 May; 18(5):329-37. PubMed ID: 8933212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.